Corporatist Big Pharma has little or no interest in non-remunerative research on infectious diseases (such as the whole class of corona viruses that have been well-known since the 1960s). Big Pharma rarely invests in prevention. It has little interest in investing in preparedness for a public health crisis. It loves to design cures. The sicker we are the more they earn. Prevention does not contribute to share-holder value. It might even diminish it. The business model applied to public health provision eliminated the surplus coping capacities that would be required in an emergency. Prevention was not even an enticing enough field of work to warrant public private partnerships.